Replimune posts Q4 net loss $55.1M; RP1 melanoma BLA on track for 2H 2024

Replimune Group, Inc.

2024-FY EPS reported -$3.24

Net loss of $55.1M for Q4 FY2024; full-year net loss $215.8M vs $174.3M prior year.
Cash, equivalents & investments $420.7M; cash runway projected into 2H 2026.
Primary analysis of IGNYTE trial (RP1 + nivolumab) in anti-PD1 failed melanoma expected Q2 2024.
BLA submission for RP1 in anti-PD1 failed melanoma planned for 2H 2024 after positive FDA CMC meeting.
First patient enrollment in Phase 3 IGNYTE-3 confirmatory trial expected 2H 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Replimune Group, Inc. reported financial results for the fourth quarter and year ended March 31, 2024.

Period: the fourth quarter and year ended March 31, 2024
Result: reported results

Exact text from the filing

Replimune Group, Inc. (the "Company") issued a news release announcing its financial results for the fourth quarter and year ended March 31, 2024

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Replimune Group, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-062296

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.